Joel Greenblatt Halozyme Therapeutics, Inc. Transaction History

Gotham Asset Management, LLC

$21.9 Billion
Q3 2025

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 252,934 shares of HALO stock, worth $17.7 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

252,934

Previous 68,052 271.68%

Holding current value

$17.7 Million

Previous $3.54 Million 424.01%

% of portfolio

0.08%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$52.92 - $78.28 $9.78 Million - $14.5 Million	184,882 Added 271.68%	252,934 $18.6 Million
Q2 2025 Aug 14, 2025	BUY	$47.91 - $70.14 $1.7 Million - $2.49 Million	35,521 Added 109.19%	68,052 $3.54 Million
Q1 2025 May 15, 2025	SELL	$47.74 - $65.16 $711,755 - $971,470	-14,909 Reduced 31.43%	32,531 $2.08 Million
Q4 2024 Feb 14, 2025	BUY	$42.57 - $61.09 $177,857 - $255,234	4,178 Added 9.66%	47,440 $2.27 Million
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $763,651 - $958,956	14,886 Added 52.46%	43,262 $2.48 Million

Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $511,833 - $709,338	-13,537 Reduced 32.3%	28,376 $1.49 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $1.89 Million - $2.35 Million	-55,975 Reduced 57.18%	41,913 $1.71 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $1.86 Million - $2.35 Million	55,782 Added 132.48%	97,888 $3.62 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $224,338 - $270,916	6,153 Added 17.11%	42,106 $1.61 Million
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $239,757 - $306,743	-7,918 Reduced 18.05%	35,953 $1.3 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $539,692 - $914,816	16,424 Added 59.84%	43,871 $1.68 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $85,848 - $127,379	-2,143 Reduced 7.24%	27,447 $1.56 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $34,869 - $46,860	-905 Reduced 2.97%	29,590 $1.17 Million
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $314,001 - $406,058	-8,407 Reduced 21.61%	30,495 $1.34 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $199,205 - $255,844	-6,231 Reduced 13.81%	38,902 $1.55 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $690,430 - $884,193	21,698 Added 92.59%	45,133 $1.82 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $420,977 - $507,974	-10,943 Reduced 31.83%	23,435 $953,000
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $463,982 - $612,949	-11,946 Reduced 25.79%	34,378 $1.56 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $991,108 - $1.29 Million	25,085 Added 118.11%	46,324 $1.93 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $9,007 - $15,223	349 Added 1.67%	21,239 $907,000
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $205 - $237	8 Added 0.04%	20,890 $549,000
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $51,236 - $84,531	3,153 Added 17.78%	20,882 $560,000
Q1 2020 May 15, 2020	BUY	$13.9 - $21.83 $246,433 - $387,024	17,729 New	17,729 $319,000
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $199,076 - $260,413	-13,334 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $5,532 - $6,439	364 Added 2.81%	13,334 $207,000
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $191,307 - $223,862	12,970 New	12,970 $223,000
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $1.04 Million - $1.15 Million	-62,201 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $906,610 - $1.09 Million	-53,741 Reduced 46.35%	62,201 $1.05 Million
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $1.98 Million - $2.46 Million	115,942 New	115,942 $2.27 Million

Others Institutions Holding HALO

# of Institutions

663

Shares Held

128M

Call Options Held

599K

Put Options Held

455K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account